Is heart failure with preserved ejection fraction a 'dementia' of the heart?
Calcium handling
Cardiac aging
Dementia
HFpEF
Left ventricular hypertrophy
Myocardial fibrosis
Journal
Heart failure reviews
ISSN: 1573-7322
Titre abrégé: Heart Fail Rev
Pays: United States
ID NLM: 9612481
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
accepted:
19
04
2021
pubmed:
29
4
2021
medline:
30
4
2022
entrez:
28
4
2021
Statut:
ppublish
Résumé
Heart failure with preserved ejection fraction (HFpEF) remains an elusive entity, due to its heterogeneous clinical profile and an arbitrarily defined nosology. Several pathophysiological mechanisms recognized as central for the development of HFpEF appear to be in common with the process of physiological aging of the heart. Both conditions are characterized by progressive impairment in cardiac function, accompanied by left ventricular hypertrophy, diastolic dysfunction, sarcomeric, and metabolic abnormalities. The neurological paradigm of dementia-intended as a progressive, multifactorial organ damage with decline of functional reserve, eventually leading to irreversible dysfunction-is well suited to represent HFpEF. In such perspective, certain phenotypes of HFpEF may be viewed as a maladaptive response to environmental modifiers, causing premature and pathological aging of the heart. We here propose that the 'HFpEF syndrome' may reflect the interplay of adverse structural remodelling and erosion of functional reserve, mirroring the processes leading to dementia in the brain. The resulting conceptual framework may help advance our understanding of HFpEF and unravel potential therapeutical targets.
Identifiants
pubmed: 33907929
doi: 10.1007/s10741-021-10114-9
pii: 10.1007/s10741-021-10114-9
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
587-594Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Udelson JE, Stevenson LW (2016) The future of heart failure diagnosis, therapy, and management circulation. 133:2671–2686. https://doi.org/10.1161/CIRCULATIONAHA.116.023518
Lewis GA, Schelbert EB, Williams SG et al (2017) Biological phenotypes of heart failure with preserved ejection fraction. J Am Coll Cardiol 70:2186–2200. https://doi.org/10.1016/j.jacc.2017.09.006
doi: 10.1016/j.jacc.2017.09.006
pubmed: 29050567
Shah SJ, Katz DH, Selvaraj S et al (2015) Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation 131:269–279. https://doi.org/10.1161/CIRCULATIONAHA.114.010637
doi: 10.1161/CIRCULATIONAHA.114.010637
pubmed: 25398313
Lam CSP, Voors AA, de Boer RA et al (2018) Heart failure with preserved ejection fraction: from mechanisms to therapies. Eur Heart J 39:2780–2792. https://doi.org/10.1093/eurheartj/ehy301
doi: 10.1093/eurheartj/ehy301
pubmed: 29905796
Fang JC (2016) Heart failure with preserved ejection fraction: a kidney disorder? Circulation 134:435–437. https://doi.org/10.1161/CIRCULATIONAHA.116.022249
doi: 10.1161/CIRCULATIONAHA.116.022249
pubmed: 27502906
Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37:2129–2200. https://doi.org/10.1093/eurheartj/ehw128
doi: 10.1093/eurheartj/ehw128
pubmed: 27206819
pmcid: 27206819
Yancy CW, Jessup M, Bozkurt B et al (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62:e147–e239. https://doi.org/10.1016/j.jacc.2013.05.019
doi: 10.1016/j.jacc.2013.05.019
pubmed: 23747642
Tini G, Olivotto I, Canepa M (2019) Letter regarding the article ‘heart failure with preserved ejection fraction: from mechanisms to therapies’ by Lam and colleagues. Eur Heart J 40:703–704. https://doi.org/10.1093/eurheartj/ehy794
doi: 10.1093/eurheartj/ehy794
pubmed: 30500889
Loffredo FS, Nikolova AP, Pancoast JR, Lee RT (2014) Heart failure with preserved ejection fraction: molecular pathways of the aging Myocardium. Circ Res 115:97–107. https://doi.org/10.1161/CIRCRESAHA.115.302929
doi: 10.1161/CIRCRESAHA.115.302929
pubmed: 24951760
pmcid: 4094348
Sharifi‐Sanjani M, Oyster Nicholas M, Tichy Elisia D et al (2017) Cardiomyocyte‐specific telomere shortening is a distinct signature of heart failure in humans. J Am Heart Assoc 6:e005086. https://doi.org/10.1161/JAHA.116.005086
Elahi FM, Miller BL (2017) A clinicopathological approach to the diagnosis of dementia. Nat Rev Neurol 13:457–476. https://doi.org/10.1038/nrneurol.2017.96
doi: 10.1038/nrneurol.2017.96
pubmed: 28708131
pmcid: 5771416
Ngo J, Holroyd-Leduc JM (2015) Systematic review of recent dementia practice guidelines. Age Ageing 44:25–33. https://doi.org/10.1093/ageing/afu143
doi: 10.1093/ageing/afu143
pubmed: 25341676
Harrington KD, Lim YY, Ames D et al (2017) Using robust normative data to investigate the neuropsychology of cognitive aging. Arch Clin Neuropsychol Off J Natl Acad Neuropsychol 32:142–154. https://doi.org/10.1093/arclin/acw106
doi: 10.1093/arclin/acw106
Moroni F, Ammirati E, Hainsworth AH, Camici PG (2020) Association of white matter hyperintensities and cardiovascular disease: the importance of microcirculatory disease. Circ Cardiovasc Imaging 13. https://doi.org/10.1161/CIRCIMAGING.120.010460
Toledo JB, Arnold SE, Raible K et al (2013) Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer’s Coordinating Centre. Brain J Neurol 136:2697–2706. https://doi.org/10.1093/brain/awt188
doi: 10.1093/brain/awt188
Scheltens P, Blennow K, Breteler MMB et al (2016) Alzheimer’s disease. Lancet Lond Engl 388:505–517. https://doi.org/10.1016/S0140-6736(15)01124-1
doi: 10.1016/S0140-6736(15)01124-1
Pardini M, Huey ED, Spina S et al (2019) FDG-PET patterns associated with underlying pathology in corticobasal syndrome. Neurology 92:e1121–e1135. https://doi.org/10.1212/WNL.0000000000007038
doi: 10.1212/WNL.0000000000007038
pubmed: 30700592
pmcid: 6442013
Stern Y (2012) Cognitive reserve in ageing and Alzheimer’s disease. Lancet Neurol 11:1006–1012. https://doi.org/10.1016/S1474-4422(12)70191-6
doi: 10.1016/S1474-4422(12)70191-6
pubmed: 23079557
pmcid: 3507991
Troncone L, Luciani M, Coggins M et al (2016) Aβ amyloid pathology affects the hearts of patients with Alzheimer’s disease: mind the heart. J Am Coll Cardiol 68:2395–2407. https://doi.org/10.1016/j.jacc.2016.08.073
doi: 10.1016/j.jacc.2016.08.073
pubmed: 27908343
pmcid: 5142757
Cannata A, Merlo M, Artico J et al (2018) Cardiovascular aging: the unveiled enigma from bench to bedside. J Cardiovasc Med 1. https://doi.org/10.2459/JCM.0000000000000694
Partridge L, Deelen J, Slagboom PE (2018) Facing up to the global challenges of ageing. Nature 561:45–56. https://doi.org/10.1038/s41586-018-0457-8
doi: 10.1038/s41586-018-0457-8
pubmed: 30185958
Olshansky SJ (2018) From lifespan to healthspan. JAMA 320:1323–1324. https://doi.org/10.1001/jama.2018.12621
doi: 10.1001/jama.2018.12621
pubmed: 30242384
Cannatà A, Camparini L, Sinagra G et al (2016) Pathways for salvage and protection of the heart under stress: novel routes for cardiac rejuvenation. Cardiovasc Res 111:142–153. https://doi.org/10.1093/cvr/cvw106
doi: 10.1093/cvr/cvw106
pubmed: 27371745
Nagueh SF, Smiseth OA, Appleton CP et al (2016) Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 17:1321–1360. https://doi.org/10.1093/ehjci/jew082
doi: 10.1093/ehjci/jew082
pubmed: 27422899
Lakatta EG, Levy D (2003) Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part II: the aging heart in health: links to heart disease. Circulation 107:346–354. https://doi.org/10.1161/01.CIR.0000048893.62841.F7
doi: 10.1161/01.CIR.0000048893.62841.F7
pubmed: 12538439
Chantler PD, Lakatta EG (2012) Arterial-ventricular coupling with aging and disease. Front Physiol 3. https://doi.org/10.3389/fphys.2012.00090
Zile MR, Baicu CF, Ikonomidis JS et al (2015) Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation 131:1247–1259. https://doi.org/10.1161/CIRCULATIONAHA.114.013215
doi: 10.1161/CIRCULATIONAHA.114.013215
pubmed: 25637629
pmcid: 4390480
Biernacka A, Frangogiannis NG (2011) Aging and cardiac fibrosis aging Dis 2:158–173
pubmed: 21837283
Rosenberry R, Munson M, Chung S et al (2018) Age-related microvascular dysfunction: novel insight from near-infrared spectroscopy. Exp Physiol 103:190–200. https://doi.org/10.1113/EP086639
doi: 10.1113/EP086639
pubmed: 29114952
Nakamura M, Sadoshima J (2018) Mechanisms of physiological and pathological cardiac hypertrophy. Nat Rev Cardiol 15:387–407. https://doi.org/10.1038/s41569-018-0007-y
doi: 10.1038/s41569-018-0007-y
pubmed: 29674714
Kovács Á, Fülöp GÁ, Kovács A et al (2016) Renin overexpression leads to increased titin-based stiffness contributing to diastolic dysfunction in hypertensive mRen2 rats. Am J Physiol Heart Circ Physiol 310:H1671-1682. https://doi.org/10.1152/ajpheart.00842.2015
doi: 10.1152/ajpheart.00842.2015
pubmed: 27059079
Linke WA, Hamdani N (2014) Gigantic business: titin properties and function through thick and thin. Circ Res 114:1052–1068. https://doi.org/10.1161/CIRCRESAHA.114.301286
doi: 10.1161/CIRCRESAHA.114.301286
pubmed: 24625729
Babušíková E, Lehotský J, Dobrota D et al (2012) Age-associated changes in Ca(2+)-ATPase and oxidative damage in sarcoplasmic reticulum of rat heart. Physiol Res 61:453–460
doi: 10.33549/physiolres.932320
Bers DM (2002) Cardiac excitation-contraction coupling. Nature 415:198–205. https://doi.org/10.1038/415198a
doi: 10.1038/415198a
pubmed: 11805843
Bers DM (2008) Calcium cycling and signaling in cardiac myocytes. Annu Rev Physiol 70:23–49. https://doi.org/10.1146/annurev.physiol.70.113006.100455
doi: 10.1146/annurev.physiol.70.113006.100455
pubmed: 17988210
Hansen M, Rubinsztein DC, Walker DW (2018) Autophagy as a promoter of longevity: insights from model organisms. Nat Rev Mol Cell Biol 19:579–593. https://doi.org/10.1038/s41580-018-0033-y
doi: 10.1038/s41580-018-0033-y
pubmed: 30006559
pmcid: 6424591
Onishi M, Yamano K, Sato M, et al (2021) Molecular mechanisms and physiological functions of mitophagy. EMBO J e104705. https://doi.org/10.15252/embj.2020104705
Anderson R, Lagnado A, Maggiorani D, et al (2019) Length-independent telomere damage drives post-mitotic cardiomyocyte senescence. EMBO J 38:e100492. https://doi.org/10.15252/embj.2018100492
Sahin E, DePinho RA (2010) Linking functional decline of telomeres, mitochondria and stem cells during ageing. Nature 464:520–528. https://doi.org/10.1038/nature08982
doi: 10.1038/nature08982
pubmed: 20336134
pmcid: 3733214
Tsao CW, Lyass A, Enserro D et al (2018) Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction. JACC Heart Fail 6:678–685. https://doi.org/10.1016/j.jchf.2018.03.006
doi: 10.1016/j.jchf.2018.03.006
pubmed: 30007560
pmcid: 6076350
Owan TE, Hodge DO, Herges RM et al (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355:251–259. https://doi.org/10.1056/NEJMoa052256
doi: 10.1056/NEJMoa052256
pubmed: 16855265
Hahn VS, Yanek LR, Vaishnav J et al (2020) Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis. JACC Heart Fail 8:712–724. https://doi.org/10.1016/j.jchf.2020.04.007
doi: 10.1016/j.jchf.2020.04.007
pubmed: 32653448
pmcid: 7604801
Shah SJ, Katz DH, Deo RC (2014) Phenotypic spectrum of heart failure with preserved ejection fraction. Heart Fail Clin 10:407–418. https://doi.org/10.1016/j.hfc.2014.04.008
doi: 10.1016/j.hfc.2014.04.008
pubmed: 24975905
pmcid: 4076705
Mohammed SF, Borlaug BA, Roger VL et al (2012) Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study. Circ Heart Fail 5:710–719. https://doi.org/10.1161/CIRCHEARTFAILURE.112.968594
doi: 10.1161/CIRCHEARTFAILURE.112.968594
pubmed: 23076838
pmcid: 3767407
Abbate A, Arena R, Abouzaki N et al (2015) Heart failure with preserved ejection fraction: refocusing on diastole. Int J Cardiol 179:430–440. https://doi.org/10.1016/j.ijcard.2014.11.106
doi: 10.1016/j.ijcard.2014.11.106
pubmed: 25465302
Borlaug BA, Lam CSP, Roger VL et al (2009) Contractility and ventricular systolic stiffening in hypertensive heart disease: insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol 54:410–418. https://doi.org/10.1016/j.jacc.2009.05.013
doi: 10.1016/j.jacc.2009.05.013
pubmed: 19628115
pmcid: 2753478
Shah SJ, Lam CSP, Svedlund S et al (2018) Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. Eur Heart J 39:3439–3450. https://doi.org/10.1093/eurheartj/ehy531
doi: 10.1093/eurheartj/ehy531
pubmed: 30165580
pmcid: 6927847
Mohammed SF, Hussain S, Mirzoyev SA et al (2015) Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation 131:550–559. https://doi.org/10.1161/CIRCULATIONAHA.114.009625
doi: 10.1161/CIRCULATIONAHA.114.009625
pubmed: 25552356
North BJ, Sinclair DA (2012) The intersection between aging and cardiovascular disease. Circ Res 110:1097–1108. https://doi.org/10.1161/CIRCRESAHA.111.246876
doi: 10.1161/CIRCRESAHA.111.246876
pubmed: 22499900
pmcid: 3366686
Paulus WJ, Tschöpe C (2013) A novel paradigm for heart failure with preserved ejection fraction. J Am Coll Cardiol 62:263–271. https://doi.org/10.1016/j.jacc.2013.02.092
doi: 10.1016/j.jacc.2013.02.092
pubmed: 23684677
Camici PG, Tschöpe C, Di Carli MF et al (2020) Coronary microvascular dysfunction in hypertrophy and heart failure. Cardiovasc Res 116:806–816. https://doi.org/10.1093/cvr/cvaa023
doi: 10.1093/cvr/cvaa023
pubmed: 31999329
Lopaschuk GD (2017) Metabolic modulators in heart disease: past, present, and future. Can J Cardiol 33:838–849. https://doi.org/10.1016/j.cjca.2016.12.013
doi: 10.1016/j.cjca.2016.12.013
pubmed: 28279520
Heinzel FR, Hegemann N, Hohendanner F et al (2020) Left ventricular dysfunction in heart failure with preserved ejection fraction-molecular mechanisms and impact on right ventricular function. Cardiovasc Diagn Ther 10:1541–1560. https://doi.org/10.21037/cdt-20-477
Yeh CH, Chou YJ, Kao CH, Tsai TF (2020) Mitochondria and calcium homeostasis: Cisd2 as a big player in cardiac ageing. Int J Mol Sci 21. https://doi.org/10.3390/ijms21239238
Kumar AA, Kelly DP, Chirinos JA (2019) Mitochondrial dysfunction in heart failure with preserved ejection fraction. Circulation 139:1435–1450. https://doi.org/10.1161/CIRCULATIONAHA.118.036259
doi: 10.1161/CIRCULATIONAHA.118.036259
pubmed: 30856000
pmcid: 6414077
Haykowsky MJ, Brubaker PH, John JM et al (2011) Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction. J Am Coll Cardiol 58:265–274. https://doi.org/10.1016/j.jacc.2011.02.055
doi: 10.1016/j.jacc.2011.02.055
pubmed: 21737017
pmcid: 3272542
Jeong MY, Lin YH, Wennersten SA et al (2018) Histone deacetylase activity governs diastolic dysfunction through a nongenomic mechanism. Sci Transl Med 10. https://doi.org/10.1126/scitranslmed.aao0144
van Heerebeek L, Borbély A, Niessen HWM et al (2006) Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 113:1966–1973. https://doi.org/10.1161/CIRCULATIONAHA.105.587519
doi: 10.1161/CIRCULATIONAHA.105.587519
pubmed: 16618817
Methawasin M, Strom JG, Slater RE et al (2016) Experimentally increasing the compliance of titin through RNA binding motif-20 (RBM20) inhibition improves diastolic function in a mouse model of heart failure with preserved ejection fraction. Circulation 134:1085–1099. https://doi.org/10.1161/CIRCULATIONAHA.116.023003
doi: 10.1161/CIRCULATIONAHA.116.023003
pubmed: 27630136
pmcid: 5069184
Duran JR, Taffet G (2007) Coronary microvascular dysfunction. N Engl J Med 356:2324–2325. https://doi.org/10.1056/NEJMc070666
Triposkiadis F, Butler J, Abboud FM et al (2019) The continuous heart failure spectrum: moving beyond an ejection fraction classification. Eur Heart J 40:2155–2163. https://doi.org/10.1093/eurheartj/ehz158
doi: 10.1093/eurheartj/ehz158
pubmed: 30957868
pmcid: 7963129
Toepfer CN, Garfinkel AC, Venturini G et al (2020) Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy. Circulation 141:828–842. https://doi.org/10.1161/CIRCULATIONAHA.119.042339
doi: 10.1161/CIRCULATIONAHA.119.042339
pubmed: 31983222
pmcid: 7077965
Ho CY, Olivotto I, Jacoby D et al (2020) Study design and rationale of EXPLORER-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy. Circ Heart Fail. https://doi.org/10.1161/CIRCHEARTFAILURE.120.006853
Signore S, Sorrentino A, Borghetti G et al (2015) Late Na(+) current and protracted electrical recovery are critical determinants of the aging myopathy. Nat Commun 6:8803. https://doi.org/10.1038/ncomms9803
doi: 10.1038/ncomms9803
pubmed: 26541940